Headline Expenditure Projections
- Pharmaceuticals: MYR6.60bn (USD2.10bn) in 2013 to MYR7.51bn (USD2.35bn) in 2014; +13.7% in local currency and +12.0% in US dollar terms. Forecast increased from Q314 to better suit current market conditions.
- Healthcare: MYR40.27bn (USD12.78bn) in 2013 to MYR43.79bn (USD13.68bn) in 2014; +8.8% in local currency and +7.1% in US dollar terms. Forecast in line with last quarter's figures.
Risk/Reward Rating: In Q414, Malaysia's Pharmaceutical Risk/Reward Rating (RRR) stood at 60, marking no change since Q114. It posts above-average scores for every indicator in the Asia Pacific region, and ranks eighth out of the 19 key markets.
Key Trends And Developments
In response to allegations that the MYR86mn (USD27.1mn) Halal hub project in Kiansam in Labuan, East Malaysia, was a mistake, former Labuan Member of Parliament Datuk Suhaili Abdul Rahman has stated that his successors are responsible for the failure of the project. 'The Halal hub was not born as a white elephant project but turned into one due to those responsible having strayed from the goal of using the hub for producing high-quality halal products,' said Suhaili (reports the Daily Express). The hub, which was initiated in 2009, aimed to add value to Labuan's marine products and cater for potential demand from the ASEAN and Gulf States. The project's plan also included processing of pharmaceuticals, herbs and cosmetics.
Malaysia, with a Muslim population of around 60%, aims to attract...
The Malaysia Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.
BMI's Malaysia Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Malaysian pharmaceutical and healthcare industry.Key Benefits
CoverageBMI Industry View & Industry SWOT
- Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Malaysia to test other views - a key input for successful budgeting and strategic business planning in the Malaysian pharmaceutical and healthcare market.
- Target business opportunities and risks in the Malaysian pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Malaysia.
- Assess the activities, strategy and market position of your competitors, partners and clients via our Company Profiles (inc. SWOTs, KPIs and latest activity) and Competitive Landscape Tables.
An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI's forecast analysis, and taken together with BMI's political, economic and business environment SWOTS, it gives a complete overview of market climate.Market Summary
Snapshot of key market characteristics, including total size of pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape.Regulatory Regime
Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as an analysis of the overall regulatory burden.Industry Developments
Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.BMI Industry Forecasts
Forecasts to end-2018 for all key industry indicators (see list below) supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:
Healthcare: Total healthcare expenditure (US$bn), healthcare expenditure (% of GDP), healthcare expenditure per capita (US$), hospital beds (per `000 population), doctors (per `000 population), birth and mortality rate (per `000 population)
Pharmaceutical market: Drug expenditure (US$bn), drug expenditure (% of GDP), drug expenditure per capita (US$)
Patented drug market: Prescription drug sales (US$bn), prescription sales (% of total sales), sales broken down by 14 therapeutic areas (cardiovascular, anti-infectives etc.)
Generic drug market: Generic product sales (US$bn), generic sales (% of total sales)
OTC drug market: OTC sales (US$bn), OTC sales (% of total sales), sales broken down by product types (analgesics, skin treatments, vitamins and minerals etc.)
Medical Devices: Medical device sales (US$bn), medical device sales (% of total healthcare market)
Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt.Competitive Landscape
The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.Company Profiles
Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI's industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.
The Malaysian pharmaceutical and healthcare markets are set to grow significantly. Promising long-term economic growth, local government support, an ageing population and a surge of chronic non-communicable diseases , sector growth will continue to be driven . However, a slowdown in economic growth in 2014, coupled with the fact that investment in the pharmaceuticals sector will take longer than expected to bring returns, present downside risks to our outlook.